TickerGuard
Buy Day today: Poor (44) Weak market breadth · no major macro event
PLYX

Polaryx Therapeutics, Inc.

Healthcare · Biotechnology

1.90$ -3.6% vs. previous close Closing price · As of: Nov 12, 2026

Ownership

Ownership Structure

Who owns Polaryx Therapeutics, Inc. (PLYX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 14.4% of the shares are freely tradable; institutional investors hold 4.6%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 4.6%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 69.9%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 14.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 0.6%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 50Mio.

Largest Shareholders

Institutions

Institutions PLYX
Name Stake (%) Shares Change (%) Date
Vanguard Capital Management, LLC 3.33 1,657,872 +0.0 06/30/2026
Geode Capital Management, LLC 0.34 170,998 +0.2 06/30/2026
Vanguard Fiduciary Trust Co 0.21 105,072 +0.5 06/30/2026
HRT FINANCIAL LLC 0.16 82,094 +0.0 06/30/2026
State Street Corp 0.12 58,104 +0.0 06/30/2026
BlackRock Inc 0.08 41,012 +0.0 06/30/2026
Jane Street Group LLC 0.06 31,441 +0.0 06/30/2026
Northern Trust Corp 0.06 27,987 +0.0 06/30/2026

Funds

Funds PLYX
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.95 1,468,014 +0.0 09/30/2026
Fidelity Extended Market Index 0.13 65,120 -0.5 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?